MeiraGTx Holdings PLC (NASDAQ:MGTX) — Market Cap & Net Worth
Market Cap & Net Worth: MeiraGTx Holdings PLC (MGTX)
MeiraGTx Holdings PLC (NASDAQ:MGTX) has a market capitalization of $760.71 Million ($760.71 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10413 globally and #2607 in its home market, demonstrating a 0.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MeiraGTx Holdings PLC's stock price $9.41 by its total outstanding shares 81446126 (81.45 Million). Analyse how efficiently does MeiraGTx Holdings PLC generate cash to see how efficiently the company converts income to cash.
MeiraGTx Holdings PLC Market Cap History: 2018 to 2026
MeiraGTx Holdings PLC's market capitalization history from 2018 to 2026. Data shows change from $785.14 Million to $766.41 Million (-5.73% CAGR).
Index Memberships
MeiraGTx Holdings PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.03% | #279 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1029 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.05% | #167 of 263 |
Weight: MeiraGTx Holdings PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MeiraGTx Holdings PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MeiraGTx Holdings PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.96x
MeiraGTx Holdings PLC's market cap is 7.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.63 Billion | $13.29 Million | -$54.75 Million | 122.67x | N/A |
| 2020 | $1.23 Billion | $15.56 Million | -$57.99 Million | 79.23x | N/A |
| 2021 | $1.93 Billion | $37.70 Million | -$79.56 Million | 51.29x | N/A |
| 2022 | $531.03 Million | $15.92 Million | -$129.62 Million | 33.36x | N/A |
| 2023 | $571.75 Million | $14.02 Million | -$84.03 Million | 40.79x | N/A |
| 2024 | $496.01 Million | $33.28 Million | -$147.79 Million | 14.90x | N/A |
| 2025 | $647.50 Million | $81.39 Million | -$114.20 Million | 7.96x | N/A |
Competitor Companies of MGTX by Market Capitalization
Companies near MeiraGTx Holdings PLC in the global market cap rankings as of May 4, 2026.
Key companies related to MeiraGTx Holdings PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
MeiraGTx Holdings PLC Historical Marketcap From 2018 to 2026
Between 2018 and today, MeiraGTx Holdings PLC's market cap moved from $785.14 Million to $ 766.41 Million, with a yearly change of -5.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $766.41 Million | +18.36% |
| 2025 | $647.50 Million | +30.54% |
| 2024 | $496.01 Million | -13.25% |
| 2023 | $571.75 Million | +7.67% |
| 2022 | $531.03 Million | -72.54% |
| 2021 | $1.93 Billion | +56.80% |
| 2020 | $1.23 Billion | -24.38% |
| 2019 | $1.63 Billion | +107.68% |
| 2018 | $785.14 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of MeiraGTx Holdings PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $760.71 Million USD |
| MoneyControl | $760.71 Million USD |
| MarketWatch | $760.71 Million USD |
| marketcap.company | $760.71 Million USD |
| Reuters | $760.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MeiraGTx Holdings PLC
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xe… Read more